Apeiron Biologics and Columbia University Have Entered Into an Exclusive License Agreement That Expands Apeiron’s Immune Checkpoint Blockade IP Portfolio

Under the terms of the agreement, Apeiron obtains worldwide exclusive rights to develop and commercialize active cellular immunotherapies under the licensed patents, which cover the inhibition of Cbl-b in T cells for the treatment of cancer.

Press release

Presseaussendung